DCT

1:26-cv-00847

MyoKardia Inc v. Aurobindo Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00847, D. Del., 07/13/2026
  • Venue Allegations: Plaintiffs allege venue is proper because Defendant Aurobindo Pharma USA, Inc. is a Delaware corporation, Defendant Aurobindo Pharma Ltd. is subject to personal jurisdiction in the district, and Defendants have represented that they do not object to venue in Delaware for this action.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the cardiac drug Camzyos® (mavacamten) infringes patents covering the mavacamten compound and its method of use for treating hypertrophic cardiomyopathy.
  • Technical Context: The technology concerns small-molecule pyrimidinedione compounds, specifically mavacamten, which functions as a cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM), a genetic heart muscle disease.
  • Key Procedural History: The lawsuit was triggered by a notice letter from Aurobindo, part of the Hatch-Waxman Act framework, informing Plaintiffs of its ANDA filing and its certification (Paragraph IV certification) that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by its proposed generic product.

Case Timeline

Date Event
2013-06-21 Priority Date for RE'050 and '883 Patents
2017-03-07 U.S. Patent No. 9,585,883 Issues
2024-07-23 U.S. Reissue Patent No. 50,050 Issues
2026-05-29 Aurobindo sends Notice Letter regarding ANDA filing
2026-06-23 Aurobindo represents it does not object to jurisdiction/venue
2026-07-13 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. 50,050 - "Pyrimidinedione Compounds"

  • Patent Identification: U.S. Reissue Patent No. 50,050 ("Pyrimidinedione Compounds"), issued July 23, 2024.

The Invention Explained

  • Problem Addressed: The patent family addresses genetic hypertrophic cardiomyopathy (HCM), a myocardial disease for which existing medical therapies are limited to treating symptoms and do not address the fundamental cause: disruptions in the function of the sarcomere, the heart's contractile unit '883 Patent, col. 1:21-34 '883 Patent, col. 2:2-8
  • The Patented Solution: The invention provides a class of novel pyrimidinedione compounds, including mavacamten, that act as cardiac myosin inhibitors RE'050 Patent, abstract These compounds are designed to reduce excess contractility in hypercontractile states by stabilizing a specific conformation of beta cardiac myosin, thereby improving cardiac elasticity and relaxation and addressing the underlying pathophysiology of HCM '883 Patent, col. 5:26-34
  • Technical Importance: These compounds represent a targeted therapeutic approach that modulates the function of the sarcomere itself, offering a potential to treat the root cause of HCM rather than only alleviating symptoms ('883 Patent, col. 2:6-12).

Key Claims at a Glance

  • The complaint asserts at least Claim 20 Compl. ¶37
  • The complaint alleges that the RE'050 patent claims recite, inter alia, a series of specifically defined compounds, including mavacamten Compl. ¶32 The text of the asserted claim is not detailed in the complaint.

U.S. Patent No. 9,585,883 - "Pyrimidinedione Compounds"

  • Patent Identification: U.S. Patent No. 9,585,883 ("Pyrimidinedione Compounds"), issued March 7, 2017.

The Invention Explained

  • Problem Addressed: The '883 Patent addresses the same problem as the RE'050 patent: the lack of therapies for HCM that target the underlying disease mechanism rather than just its symptoms '883 Patent, col. 2:2-8
  • The Patented Solution: The patent claims methods of treating HCM by administering an effective amount of the pyrimidinedione compounds described in the specification, including mavacamten, to a subject in need thereof '883 Patent, abstract '883 Patent, col. 9:51-54 This protects the specific use of the compounds for treating this cardiac disorder.
  • Technical Importance: This patent provides method-of-use protection for the novel compounds, which is critical for pharmaceutical inventions where a drug's value is tied to its approved medical indications.

Key Claims at a Glance

  • The complaint asserts at least Claim 18, which depends from independent Claim 1 Compl. ¶56
  • The essential elements of independent Claim 1 are:
    • A method of treating hypertrophic cardiomyopathy (HCM),
    • comprising administering to a subject in need thereof
    • an effective amount of a compound having a specified chemical structure (a pyrimidinedione) or a pharmaceutically acceptable salt thereof, where the structure encompasses mavacamten.

III. The Accused Instrumentality

Product Identification

  • Aurobindo's proposed generic version of Camzyos® (mavacamten) capsules, in 2.5 mg, 5 mg, 10 mg, and 15 mg dosage strengths, as described in ANDA No. 221654 ("Aurobindo's ANDA Product") Compl. ¶2 Compl. ¶3

Functionality and Market Context

  • The accused product contains the active pharmaceutical ingredient mavacamten Compl. ¶27
  • The complaint alleges that the proposed product is a generic version of the plaintiffs' commercial product, Camzyos®, and will be used to treat adults with obstructive hypertrophic cardiomyopathy, the same indication for which Camzyos® is approved Compl. ¶27 Compl. ¶28 The infringement action is based on the statutory act of filing the ANDA to obtain FDA approval for this generic product prior to the expiration of the patents-in-suit Compl. ¶2 Compl. ¶39

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

RE50,050 Infringement Allegations

Claim Element (from allegations regarding Claim 20) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound which is mavacamten, or a pharmaceutically acceptable salt thereof. Aurobindo's ANDA Product is a generic version of Camzyos® and contains the active ingredient mavacamten. ¶27; ¶28 RE'050 Patent, abstract; RE'050 Patent, col. 6:49-6:51

9,585,883 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating hypertrophic cardiomyopathy (HCM), The use of Aurobindo's ANDA Product in accordance with its proposed labeling is for the treatment of adults with obstructive hypertrophic cardiomyopathy. ¶27; ¶56 '883 Patent, col. 9:51-52
comprising administering to a subject in need thereof an effective amount Aurobindo's proposed labeling will instruct and direct medical professionals and patients to administer the ANDA Product to subjects. ¶57 '883 Patent, col. 9:52-53
of a compound having the formula: [formula] or a pharmaceutically acceptable salt thereof [encompassing mavacamten]. Aurobindo's ANDA Product contains the active ingredient mavacamten. ¶27; ¶52 '883 Patent, col. 9:53-54; '883 Patent, col. 4:50-6:44
  • Identified Points of Contention:
    • Validity: In ANDA litigation, where the generic product is a bioequivalent copy, the primary defense is often patent invalidity. The complaint notes that Aurobindo's Paragraph IV certifications assert that the patents-in-suit are invalid and/or unenforceable Compl. ¶35 Compl. ¶55 The case will likely involve significant disputes over whether the claimed inventions would have been obvious or were not adequately described or enabled by the patent specification.
    • Infringement of Method-of-Use Claims: For the '883 patent, a key question may be whether Aurobindo's proposed product labeling will induce infringement of the claimed method. This could involve "carve-out" strategies, where a generic manufacturer attempts to omit patented indications from its label to avoid inducement. The complaint alleges that the use directed by the proposed labeling would infringe Compl. ¶57, setting the stage for this dispute.

V. Key Claim Terms for Construction

  • The Term: "treating hypertrophic cardiomyopathy (HCM)" (from Claim 1 of the '883 patent)
  • Context and Importance: The definition of this term is critical for the method-of-use claims of the '883 patent. Practitioners may focus on this term because a defendant could argue its product is intended only for symptomatic relief, not for "treating" the underlying disease itself, in an attempt to design around the claim. The patent's own text creates a potential ambiguity by distinguishing the invention from prior art that only treats symptoms.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent states that treatment can refer to "any indicia of success in the treatment or amelioration of a pathology... including any objective or subjective parameter such as abatement; remission; diminishing of symptoms" '883 Patent, col. 6:49-54 This language could support a construction that includes mere symptom relief.
    • Evidence for a Narrower Interpretation: The "Background of the Invention" section criticizes prior therapies because they are "limited to the treatment of symptoms and does not address the fundamental, underlying cause of disease" '883 Patent, col. 2:2-5 This distinction could be used to argue that "treating HCM" as claimed requires more than just symptomatic relief and must address the root cause, potentially narrowing the claim's scope.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Aurobindo will actively induce infringement of the '883 patent because its proposed product labeling will instruct medical providers and patients to use the generic product in a manner that directly infringes the patented method Compl. ¶61 The complaint also pleads contributory infringement, alleging the product is not suitable for substantial non-infringing use Compl. ¶58
  • Willful Infringement: The complaint alleges that Aurobindo knew of the patents-in-suit, at the latest, through their listing in the FDA's Orange Book and through the statutorily required notice letter Compl. ¶33-34 Compl. ¶53-54 The complaint further alleges that "Notwithstanding Aurobindo's knowledge of the claims," it has continued to assert its intent to market the product, which may form the basis for a willfulness claim Compl. ¶42 Compl. ¶62

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue for both patents will be one of validity: can Aurobindo prove by clear and convincing evidence that the claims covering the mavacamten compound (RE'050 patent) and its method of use for treating HCM ('883 patent) are invalid for reasons such as obviousness or lack of enablement, as asserted in its Paragraph IV certifications?
  • A key question for the '883 patent will be one of induced infringement: will Aurobindo's proposed product label contain instructions that direct users to perform all the steps of the claimed method of "treating" HCM, or can it successfully "carve out" the patented use to avoid liability?
  • A related legal and factual question will be the scope of the safe harbor under 35 U.S.C. § 271(e)(1). The dispute will center on whether Aurobindo's activities are "solely for uses reasonably related to the development and submission of information under a Federal law which regulates... drugs," or if they constitute commercial acts of infringement.
Loading Complaint